A Booming Market Drives the Growth of Cancer Generics

Backed by patent expiries of blockbuster drugs and feasible regulatory environment, the cancer generics market is expected to grow at a CAGR of 27% during 2010-2014.

NOIDA, India (prHWY.com) November 9, 2011 - According to our new research report, "Cancer Generics Market Analysis", market for cancer generics is anticipated to grow at a CAGR of around 27% during 2010-2014 and all classes of drugs are set to experience splendid growth. As oncology products sales worth of billions are at risk from generic erosion in the coming future and the imminent introduction of a regulatory pathway for bio-generics is possible, the world is well poised to witness strong demand for cancer generic drugs.

Our report provides a deep insight of the key oral generic cancer drugs. Casodex, for instance, is mainly used for the treatment of prostate cancer and is considered to be the leading anti-androgen drug in the US, European countries, and Japan. The generic version of Casodex is sold by Mylan, Actavis, Sun Pharma, etc. and it is believed that the generic version of Casodex would cost around 77% less than its branded version.

Our report, "Cancer Generics Market Analysis", categorizes the global cancer generics market into oral generic cancer drugs and generic cancer injectables. It also covers comprehensive information on the current status of the cancer generic drugs market and provides a deep analysis of key developments. Moreover, it investigates the current market trends and effectively analyzes their impact on the present and future performance of the sector.

Our report is an outcome of extensive research and in-depth analysis of the cancer generics market that provides reliable statistics on the pipeline drugs and cancer therapeutics market. It also gives a true picture of the cost of key branded and generic cancer drugs and difference among them. Last though not the least, our report provides a concrete description of the key players and information about their generic products. Overall, the report is likely to provide clients with an optimum source of knowledge and data on the cancer generic drugs.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM353.htm

Check DISCOUNTED REPORTS on: http://www.rncos.com/promotion.htm

ABOUT US:

Established in 2002, RNCOS is a premier source of industry research and information provider. We bring first-hand information and prudent analysis on different industries, technologies, economic and non-economic market parameters, potential markets, and key competitors, to help clients identify prospective growth areas and gain competitive edge.

###

Tag Words: hospira, ranbaxy

Categories: Health

Press Release Contact
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707

Link To This Press Release:

URL HTML Code